Neuphoria Therapeutics Inc.
16.30%
875,328
1191070
64136E102
Nov 17, 2025
Nov 18, 2025, 08:25 AM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | Partnership | 16.30% | 875,328 | 0 | 875,328 |
| Weston Nichols | Individual | 16.30% | 875,328 | 0 | 875,328 |
Disclosure Items (5)
Common Stock, par value $0.00001 per share
Neuphoria Therapeutics Inc.
100 SUMMIT DR, BURLINGTON, MA, 01803
Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: See rows (11) and (13) of the cover pages to this Amendment No. 2 for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by the Reporting Persons. The Reporting Persons have not disposed of any shares beneficially owned by them since the date of the Original Schedule 13D. Rather, the reduction in percentage of Common Stock reported as beneficially owned by the Reporting Persons as reported in row (13) of the cover pages to this Amendment No. 2, versus the percentage previously reported by the Reporting Persons, is based on an increase in the number of outstanding shares of the Company's Common Stock since the date of the Original Schedule 13D. Specifically, the percentage in row (13) of the cover pages is based on 5,377,329 shares of Common Stock outstanding as of November 13, 2025, as reported in the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 14, 2025.
Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 4 of this Amendment No. 2 is incorporated herein by reference.
Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.3: Nov. 18 Letter to the Board, dated November 18, 2025